Company Contact:
Chris Adams
+1 617-957-985
cadams@ceeable.com

Caltech issued new patents for the automated detection and analysis of visual field test results for optic nerve and retinal disease

New patents extend the technology platform for a cloud-based mobile digital health solution for detecting and diagnosing retinal disease

Somerville, Mass., October 12, 2016 – The California Institute of Technology has been granted United States Patents 9,122,956 and 9,424,489, for "Automated Feature Analysis, Comparison, and Anomaly Detection." This set of patents discloses novel methods and systems for automated data analysis based on a proprietary algorithm. Data can be automatically analyzed to determine features and test results in different applications, such as in ophthalmology. The technology will be used to automatically determine the results from visual field testing of optic nerve and retinal disease. Ceeable has an exclusive license to the technology from Caltech.

"This set of patents is a powerful application of machine learning and offer an ability to aid in the automated detection of eye disease on a digital platform", says Dr. Wolfgang Fink, Chief Technology Officer and inventor of the Ceeable technology. In particular, the patented data analysis framework allows for the comparison of visual field data between patients. Moreover, it enables the ability to track how visual fields develop over time due to disease progression or treatment.

About Ceeable
Ceeable, Inc. is a leader in digital mobile health for ophthalmology. The Ceeable Visual Field Analyzer (CVFA) is cloud-based digital platform used to detect and diagnose retinal disease. There are more that 300 million people worldwide that suffer from retinal disease. The Ceeable technology has the ability to reach more people worldwide than any currently available retinal diagnostic technology. Better patient management of eye disease will reduce healthcare systems costs and help to prevent blindness.

###